Related references
Note: Only part of the references are listed.Effect of APOE genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's disease
Richard E. Kennedy et al.
ALZHEIMERS & DEMENTIA (2014)
Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory
Jeremy Hobart et al.
ALZHEIMERS & DEMENTIA (2013)
Results of the GAP 160701 study: A phase 3 clinical trial of intravenous immunoglobulin for mild-to-moderate Alzheimer's disease
Norman Relkin
Alzheimers & Dementia (2013)
Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force
Bruno Vellas et al.
ALZHEIMERS & DEMENTIA (2013)
Predicting missing biomarker data in a longitudinal study of Alzheimer disease
Raymond Y. Lo et al.
NEUROLOGY (2012)
Estimating power with effect size versus slop differences: Both means and variance matter
Lon S. Schneider et al.
ALZHEIMERS & DEMENTIA (2011)
Errors in ADAS-Cog Administration and Scoring May Undermine Clinical Trials Results
K. Schafer et al.
CURRENT ALZHEIMER RESEARCH (2011)
How Should We Deal with Missing Data in Clinical Trials Involving Alzheimer's Disease Patients?
N. Coley et al.
CURRENT ALZHEIMER RESEARCH (2011)
The influence of ApoE4 on clinical progression of dementia: a meta-analysis
Charlotte L. Allan et al.
INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY (2011)
Epidemiology of Alzheimer disease
Christiane Reitz et al.
NATURE REVIEWS NEUROLOGY (2011)
Alzheimer's Disease Clinical Trials: Changing the Paradigm
Jeffrey L. Cummings
CURRENT PSYCHIATRY REPORTS (2011)
Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials
Lon S. Schneider et al.
ALZHEIMERS & DEMENTIA (2010)
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Michael Gold et al.
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2010)
The ADAS-cog in Alzheimer's disease clinical trials: psychometric evaluation of the sum and its parts
Stefan J. Cano et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2010)
Conducting Meta-Analyses in R with the metafor Package
Wolfgang Viechtbauer
JOURNAL OF STATISTICAL SOFTWARE (2010)
Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical characterization
R. C. Petersen et al.
NEUROLOGY (2010)
ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease
D. J. Stone et al.
PHARMACOGENOMICS JOURNAL (2010)
The Coalition Against Major Diseases: Developing Tools for an Integrated Drug Development Process for Alzheimer's and Parkinson's Diseases
K. Romero et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA Datasets
Ohidul Siddiqui et al.
JOURNAL OF BIOPHARMACEUTICAL STATISTICS (2009)
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
S. Salloway et al.
NEUROLOGY (2009)
Donepezil treatment of patients with MCI A 48-week randomized, placebo-controlled trial
R. S. Doody et al.
NEUROLOGY (2009)
Growth hormone secretagogue MK-677 No clinical effect on AD progression in a randomized trial
J. J. Sevigny et al.
NEUROLOGY (2008)
Controversies in Alzheimer's disease drug development
Jeffrey L. Cummings
INTERNATIONAL REVIEW OF PSYCHIATRY (2008)
The design of simulation studies in medical statistics
Andrea Burton et al.
STATISTICS IN MEDICINE (2006)
Caution regarding the use of pilot studies to guide power calculations for study proposals
HC Kraemer et al.
ARCHIVES OF GENERAL PSYCHIATRY (2006)
Vitamin E and donepezil for the treatment of mild cognitive impairment
RC Petersen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test
ST Brookes et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2004)
Rofecoxib - No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study
SA Reines et al.
NEUROLOGY (2004)
Impact of APOE in mild cognitive impairment
MR Farlow et al.
NEUROLOGY (2004)
Rate of cognitive decline and mortality in Alzheimer's disease
JS Hui et al.
NEUROLOGY (2003)
Share Paper
